Rockwell Medical
RMTI · Nasdaq · United States
Share price · RMTI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RMTI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026+17.1%
- 7 Oct 2026+7.5%
Nothing announced by RMTI that day or the session before.
- 28 Aug 2026+5.4%
Nothing announced by RMTI that day or the session before.
- 29 Jun 2026-9.2%
- 16 Jun 2026+6.3%
- 11 Jun 2026-7.5%
Nothing announced by RMTI that day or the session before.
- 6 May 2026-5.8%
Nothing announced by RMTI that day or the session before.
- 20 Jan 2026+31.3%
- 5 Jan 2026+15.1%
- 26 Dec 2025+6.2%
Nothing announced by RMTI that day or the session before.
Share of unusual movement by asset
For each asset, the share of RMTI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 32% |
| Sessions with no dated event | — | 68% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Ferric pyrophosphate citrate(Triferic) | Approved | Iron-replacement therapy delivered via dialysateSmall molecule | Chronic Kidney DiseaseIron Deficiency Anemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $19M | $0.1M | $11M+ $12M short-term inv. | $2.3M-$1.5M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $18M | <$0.1M | $11M+ $14M short-term inv. | $1.2M$2.1M operating cash flow | report ↗ |
| 2026-Q1 | $17M | — | $9.6M+ $14M short-term inv. | $1.6M-$0.2M operating cash flow | report ↗ |
| 2025-Q3 | $16M | $0 | $14M+ $10M short-term inv. | $1.8M-$1.3M operating cash flow | report ↗ |
| 2025-Q2 | $16M | $0 | $12M+ $5.9M short-term inv. | $1.5M$1.8M operating cash flow | report ↗ |
| 2025-Q1 | $19M | $0 | $11M+ $5.9M short-term inv. | $1.5M-$3.5M operating cash flow | report ↗ |
| 2024-Q3 | $28M | $0 | $12M+ $5.9M short-term inv. | —$4.3M operating cash flow | report ↗ |
| 2024-Q2 | $26M | $0 | $12M+ $0 short-term inv. | —$1.4M operating cash flow | report ↗ |
| 2024-Q1 | $23M | <$0.1M | $6.6M+ $2.0M short-term inv. | $1.7M-$2.4M operating cash flow | report ↗ |
| 2023-Q3 | $24M | $0.5M | $7.8M+ $4.0M short-term inv. | $1.9M-$3.8M operating cash flow | report ↗ |
| 2023-Q2 | $18M | $0.2M | $9.0M+ $5.9M short-term inv. | $3.3M-$1.7M operating cash flow | report ↗ |
| 2023-Q1 | $20M | $0.3M | $11M+ $5.9M short-term inv. | $1.8M-$3.9M operating cash flow | report ↗ |
| 2022-Q3 | $19M | $0.5M | $13M+ $15M short-term inv. | $4.2M-$1.1M operating cash flow | report ↗ |
| 2022-Q2 | $19M | $0.9M | $31M+ $0 short-term inv. | $5.0M-$5.9M operating cash flow | report ↗ |
| 2022-Q1 | $16M | $1.6M | $9.9M+ $0 short-term inv. | $7.2M-$9.8M operating cash flow | report ↗ |
| 2021-Q3 | $16M | $1.2M | $23M+ $9.8M short-term inv. | $7.6M-$7.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $69M | $0 | $11M+ $14M short-term inv. | $1.3M-$0.7M operating cash flow | report ↗ |
Rockwell Medical reported FY2025 revenue of $69.26M, down 31.8% YoY from $101.49M, and R&D spend of $0M, down 100.0% YoY from $0.02M. Cash and cash equivalents were $10.71M, while cash and cash equivalents plus investments available-for-sale totaled $25.0M at year-end; the company recorded a net loss of $5.31M for the year.
Management said 2025 results were in line with annual guidance and that the company remained profitable on an Adjusted EBITDA basis for the second consecutive year. 2026 guidance projects Adjusted EBITDA of $1M to $2M with positive operating cash flow. During the year, Rockwell extended its purchase agreement with one of the largest U.S. dialysis providers through December 2026 with increased pricing, added 30 new western U.S. customers in the fourth quarter, signed a multi-year agreement with Innovative Renal Care, and added a 510(k)-approved single-use bicarbonate cartridge to its portfolio, along with several leadership appointments.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $101M | <$0.1M | $16M+ $5.9M short-term inv. | $0.1M$4.2M operating cash flow | report ↗ |
| 2023-FY | $84M | $1.1M | $9.0M+ $1.9M short-term inv. | $2.1M-$9.4M operating cash flow | report ↗ |
| 2022-FY | $73M | — | $10M+ $11M short-term inv. | $4.7M-$17M operating cash flow | report ↗ |
| 2021-FY | $62M | — | $13M+ $9.2M short-term inv. | $8.2M-$34M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 3 sales ($12K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | Strobeck Mark · director, President and CEO | Open-market sale | 1,000 | $8.42 | $8K | Form 4 |
| 2026-07-01 | Strobeck Mark · director, President and CEO | Award / grant | 30,000 | — | — | Form 4 |
| 2026-07-01 | Neri Jesse · SVP and CFO | Award / grant | 15,000 | — | — | Form 4 |
| 2026-07-01 | TIMMINS MEGAN C. · EVP, CLO & Secretary | Award / grant | 15,000 | — | — | Form 4 |
| 2026-07-01 | Hunter Heather · Chief Operating Officer | Award / grant | 15,000 | — | — | Form 4 |
| 2026-07-01 | Chole Timothy · SVP and CCO | Award / grant | 15,000 | — | — | Form 4 |
| 2026-07-01 | COOPER JOHN G · director | Award / grant | 9,633 | — | — | Form 4 |
| 2026-07-01 | Radie Robert S · director | Award / grant | 9,633 | — | — | Form 4 |